COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

The PRIMAVERA Study: Reduxine Safety Monitoring in Patients With Alimentary Obesity (Primavera)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01773733
Recruitment Status : Unknown
Verified August 2014 by Promomed, LLC.
Recruitment status was:  Active, not recruiting
First Posted : January 23, 2013
Last Update Posted : August 4, 2014
Information provided by (Responsible Party):
Promomed, LLC

Brief Summary:
The aim of this study is to summarize the data on efficacy and safety of Reduxine administration in the routine clinical practice according to the approved indications.

Condition or disease
Alimentary Obesity

Detailed Description:

Secondary objectives:

  • to study the structure of the population of patients with the diet induced obesity with body mass index (BMI) 30 kg/m2 or diet induced obesity with BMI ≥27 kg/m2 associated with type 2 diabetes mellitus in respect of comorbidities and concomitant treatment to determine the areas for further investigations.
  • to introduce the elements of control of adverse cardiovascular risks into the routine clinical practice: questionnaire concerning enrollment criteria for Reduxine treatment initiation, algorithm of Reduxine administration and treatment efficacy and safety monitoring (assessment schedule).
  • to assess the effects of the treatment of overweight and obesity with Reduxine on patients' quality of life parameters.

The Time Frame: the follow up of the study patients will be performed during six month to one year. Exception - premature discontinuation from the study.

The scheduled visits of the patients to the investigational centres are: Week0 (inclusion of the patient), Week 2, 4, 6, 8, 10, 12, 16, 20, 24, 36 and Week 48.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 100000 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: All-Russia Non-interventional Program of Reduxine Safety Monitoring for Weight Reduction in Patients With Alimentary Obesity in the Routine Clinical Practice
Study Start Date : November 2012
Estimated Primary Completion Date : July 2015
Estimated Study Completion Date : December 2015

BMI ≥ 30
BMI ≥27 kg/m2 associated with DM2

Primary Outcome Measures :
  1. weight reduction, kg [ Time Frame: Dec 2015 ]

Secondary Outcome Measures :
  1. Heart Rate, bpm [ Time Frame: Dec 2015 ]
  2. Blood pressure, mmHg [ Time Frame: Dec 2015 ]
  3. Adverse events [ Time Frame: Dec 2015 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Men and women of 18-65 years old, in the random gender and demographical proportion, with the diagnosed overweight (BMI ≥ 27 and < 30) and obesity (BMI ≥ 30).

Inclusion Criteria:

  • Men and women of 18-65 years of age to whom, in the doctor's opinion, the on-label use of Reduxine is indicated.
  • Patient's desire and ability to participate in the program and fulfill the doctor's instructions designed to achieve the treatment goal and the program requirements compliance.
  • Signed informed consent form for participation in the program.

Exclusion Criteria:

- Patients under age of 18 or older than 65;

Current or the history of:

  • coronary artery disease (e.g. angina, myocardial infraction);
  • congestive heart failure;
  • tachycardia;
  • peripheral arterial occlusive disease;
  • arrythmia;
  • Uncontrolled arterial hypertension >145/90 mm Hg;
  • Hypersensitivity to sibutramine or any components of Reduxine®;
  • Current use of monoamineoxidase inhibitors (IMAO) or their use within the last 2 weeks;
  • Current use of other central acting weight reducing drugs or their use within the last 2 weeks;
  • Use on other drugs affecting the central nervous system (e.g. antidepressants, neuroleptics); tryptophan-containing drugs indicated for sleep disturbance;
  • Severe eating disorder (anorexia nervosa or bulimia);
  • Mental disease;
  • Gilles de la Tourette syndrome (generalized tics);
  • Body mass index ≤30 kg/m2 or ≤27 kg/m2 in the presence of concomitant diseases (dyslipidemia, diabetes);
  • Organic cause of obesity (e.g. hypothyrosis);
  • Thyrotoxicosis;
  • Sever liver and/or kidney function abnormality;
  • Benign prostatic hyperplasia;
  • Phaeochromocytoma;
  • Narrowangle glaucoma;
  • Documented pharmacologic, drug or alcohol addiction;
  • Pregnancy and lactation;
  • Refusal to sign the informed consent form for participation in the program;
  • Participation in a clinical study of any new drug product within 90 days prior to the screening visit.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01773733

Layout table for location information
Russian Federation
Promomed Llc
Moscow, Moscow region, Russian Federation, 299090
Sponsors and Collaborators
Promomed, LLC
Layout table for additonal information
Responsible Party: Promomed, LLC Identifier: NCT01773733    
First Posted: January 23, 2013    Key Record Dates
Last Update Posted: August 4, 2014
Last Verified: August 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Nutrition Disorders
Body Weight